AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the publication of results from its ongoing Phase 2a clinical study of its investigational treatment for treatment-resistant depression (TRD), BPL-003, reporting rapid and sustained antidepressant effects in a small patient cohort. The data, published in the Journal of Psychopharmacology, comes from Cohort 1 of the four-part trial.